HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CDP 840

RN refers to (R)-isomer; structure given in first source

Also Known As:

4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; CDP-840; CDP840

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - CDP 840: 8

Experts

1.	Itami, Kenichiro: 1 article (08/2005)
2.	Mineno, Masahiro: 1 article (08/2005)
3.	Muraoka, Nobuhiro: 1 article (08/2005)
4.	Yoshida, Jun-ichi: 1 article (08/2005)
5.	Alexander, R P: 1 article (06/2002)
6.	Allen, R A: 1 article (06/2002)
7.	Barnes, D: 1 article (06/2002)
8.	Boyce, B: 1 article (06/2002)
9.	Boyd, E C: 1 article (06/2002)
10.	Brown, J A: 1 article (06/2002)

Related Diseases

1.	Nausea 05/01/1997 - "In all studies, CDP840 was well-tolerated, with no patients reporting nausea. "
2.	Asthma (Bronchial Asthma) 07/01/1996 - "The novel series of tri-aryl ethanes, of which CDP840 is the lead compound, could be the basis of an orally active prophylactic treatment for human asthma." 08/19/2005 - "A rapid synthesis of CDP840 (a potential therapeutic agent for asthma), using 2-pyrimidyl vinyl sulfide as a platform, has been established. " 02/01/1998 - "The activity of CDP-840, a novel, selective phosphodiesterase IV inhibitor was determined in a leukotriene-dependent non-human primate model of allergic asthma. "
3.	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 07/01/1996 - "3. Antigen-induced pulmonary eosinophilia in sensitized guinea-pigs was reduced dose-dependently by CDP840 (0.01-1 mg kg-1, i.p.) and intracellular EPO levels were significantly higher. " 07/01/1996 - "Antigen-induced pulmonary eosinophilia was reduced (93%) in budesonide and (85%) in CDP840 treated rabbits. "
4.	Inflammation (Inflammations) 06/03/2002 - "CDP840 is non-emetic in the ferret at 30mgkg(-1) (po), active in models of inflammation and reverses ozone-induced bronchial hyperreactivity in the guinea pig." 07/01/1996 - "1. The effects of the inhaled corticosteroid budesonide and a novel PDE 4 inhibitor CDP840 given systematically, were evaluated in a model of antigen-induced airway inflammation in the rabbit. "
5.	Eosinophilia 07/01/1996 - "CDP840 is stereo-selective since its S enantiomer (CT 1731) is 10-50 times less active against all forms of PDE 4 tested while both enantiomers are inactive (IC50S: > 100 microM) against PDE types 1, 2, 3 and 5. 2. Oral administration of CDP840 caused a dose-dependent reduction of interleukin-5 (IL-5)-induced pleural eosinophilia in rats (ED50 = 0.03 mg kg-1). " 07/01/1996 - "CDP840 and budesonide also prevented antigen-induced AHR and eosinophilia in the immunised rabbit." 07/01/1996 - "The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4."

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Rolipram
3.	Phosphoric Diester Hydrolases (Phosphodiesterases)
4.	Ozone
5.	Antigens
6.	Type 4 Cyclic Nucleotide Phosphodiesterases
7.	Budesonide (Pulmicort)
8.	Cholinergic Agents (Cholinergics)
9.	Interleukin-5 (Interleukin 5)
10.	Leukotrienes

Related Therapies and Procedures

1.	Oral Administration